The stock of Affimed N.V (NASDAQ: AFMD) has decreased by -29.10 when compared to last closing price of 2.13. Despite this, the company has experienced a -34.91% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-09 that MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the first-in-human Phase 1 study of AFM28, showed promising results in R/R AML, with signs of clinical efficacy and a well-managed safety profile at doses up to 300 mg weekly.
Is It Worth Investing in Affimed N.V (NASDAQ: AFMD) Right Now?
The 36-month beta value for AFMD is at 2.06. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AFMD is 13.02M, and currently, shorts hold a 4.70% of that float. The average trading volume for AFMD on December 17, 2024 was 199.89K shares.
AFMD’s Market Performance
AFMD’s stock has seen a -34.91% decrease for the week, with a -56.60% drop in the past month and a -62.43% fall in the past quarter. The volatility ratio for the week is 8.68%, and the volatility levels for the past 30 days are at 10.76% for Affimed N.V The simple moving average for the last 20 days is -39.43% for AFMD stock, with a simple moving average of -66.39% for the last 200 days.
Analysts’ Opinion of AFMD
Many brokerage firms have already submitted their reports for AFMD stocks, with H.C. Wainwright repeating the rating for AFMD by listing it as a “Buy.” The predicted price for AFMD in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 12, 2022 of the previous year 2022.
Stifel, on the other hand, stated in their research note that they expect to see AFMD reach a price target of $2, previously predicting the price at $9. The rating they have provided for AFMD stocks is “Hold” according to the report published on October 10th, 2022.
AFMD Trading at -50.26% from the 50-Day Moving Average
After a stumble in the market that brought AFMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.13% of loss for the given period.
Volatility was left at 10.76%, however, over the last 30 days, the volatility rate increased by 8.68%, as shares sank -54.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.11% lower at present.
During the last 5 trading sessions, AFMD fell by -37.50%, which changed the moving average for the period of 200-days by -78.99% in comparison to the 20-day moving average, which settled at $2.49. In addition, Affimed N.V saw -75.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AFMD
Current profitability levels for the company are sitting at:
- -80.05 for the present operating margin
- 1.0 for the gross margin
The net margin for Affimed N.V stands at -79.78. The total capital return value is set at -3.03. Equity return is now at value -151.46, with -88.07 for asset returns.
Based on Affimed N.V (AFMD), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -9.54. The debt to equity ratio resting at 0.47. The interest coverage ratio of the stock is -51.7.
Currently, EBITDA for the company is -102.38 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 30.89. The receivables turnover for the company is 0.19for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In conclusion, Affimed N.V (AFMD) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
